Literature DB >> 20012942

Concentration of the macrolide antibiotic tulathromycin in broncho-alveolar cells is influenced by comedication of rifampicin in foals.

Monica Venner1, Jette Peters, Nina Höhensteiger, Birthe Schock, Alexa Bornhorst, Markus Grube, Ulrike Adam, Eberhard Scheuch, Werner Weitschies, Dieter Rosskopf, Heyo K Kroemer, Werner Siegmund.   

Abstract

Macrolide antibiotics penetrate in the lung against steep concentration gradients into the epithelial lining fluid (ELF) and broncho-alveolar cells (BAC). Since they interact with ABCB1, ABCC2, and organic anion transporting proteins (OATPs), which are localized to lung tissue, pulmonary concentration may be influenced by rifampicin (RIF), an inducer and modulator of efflux and uptake transporters. We measured concentrations of tulathromycin (TM) in plasma, ELF and BAC in 21 warm-blooded foals 24 and 192 h after first and last intramuscular injection of 2.5 mg/kg TM once weekly for 6 weeks. In 11 foals, TM was combined with RIF (10 mg/kg twice daily), and mRNA expression of ABCB1 and ABCC2 in BAC was assessed before and after RIF. Affinity of TM to ABCB1 and ABCC2 was measured by transport assays using cell monolayers and membrane vesicles of MDCKII and 2008 cells transfected with ABCB1 and ABCC2, respectively. At steady state, TM concentrated manifold in ELF and BAC. Comedication of RIF significantly decreased the AUC of TM (18.5 +/- 4.0 versus 24.4 +/- 3.7 microg x h/ml, p < 0.05) and lowered its concentrations in plasma (24 h, 0.17 +/- 0.05 versus 0.24 +/- 0.05 microg/ml; 192 h, 0.05 +/- 0.01 versus 0.06 +/- 0.01 microg/ml) and BAC (24 h, 0.84 +/- 0.36 versus 1.56 +/- 1.02 microg/ml; 192 h, 0.60 +/- 0.23 versus 1.23 +/- 0.90 microg/ml, all p < 0.05). Treatment with rifampicin did not markedly induce ABCB1 and ABCC2 expression. TM had no affinity to ABCB1 and ABCC2 in vitro. Concentration of TM in the lung of foals was significantly lowered by comedication of rifampicin most likely caused by extrapulmonary mechanisms leading to lower plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20012942     DOI: 10.1007/s00210-009-0481-1

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  35 in total

1.  Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy.

Authors:  Hisham M Ziglam; David R Baldwin; Ian Daniels; Jenny M Andrew; Roger G Finch
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

2.  Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems.

Authors:  Yvonne Y Lau; Hideaki Okochi; Yong Huang; Leslie Z Benet
Journal:  J Pharmacol Exp Ther       Date:  2005-10-28       Impact factor: 4.030

Review 3.  Rifampin.

Authors:  B Farr; G L Mandell
Journal:  Med Clin North Am       Date:  1982-01       Impact factor: 5.456

4.  Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver.

Authors:  Nadine Albermann; Friedrich Hubertus Schmitz-Winnenthal; Kaspar Z'graggen; Christine Volk; Michael Marcus Hoffmann; Walter Emil Haefeli; Johanna Weiss
Journal:  Biochem Pharmacol       Date:  2005-09-15       Impact factor: 5.858

5.  The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3.

Authors:  Annick Seithel; Sonja Eberl; Katrin Singer; Daniel Auge; Georg Heinkele; Nadine B Wolf; Frank Dörje; Martin F Fromm; Jörg König
Journal:  Drug Metab Dispos       Date:  2007-02-12       Impact factor: 3.922

6.  Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses.

Authors:  K M Olsen; G San Pedro; L P Gann; P O Gubbins; D M Halinski; G D Campbell
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

7.  Reduced intracellular activity of antibiotics against Listeria monocytogenes in multidrug resistant cells.

Authors:  T Nichterlein; M Kretschmar; A Schadt; A Meyer; A Wildfeuer; H Laufen; H Hof
Journal:  Int J Antimicrob Agents       Date:  1998-05       Impact factor: 5.283

8.  Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.

Authors:  Keith A Rodvold; Larry H Danziger; Mark H Gotfried
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 9.  Rhodococcus equi.

Authors:  Wim G Meijer; John F Prescott
Journal:  Vet Res       Date:  2004 Jul-Aug       Impact factor: 3.683

10.  P-glycoprotein expression and function in circulating blood cells from normal volunteers.

Authors:  W T Klimecki; B W Futscher; T M Grogan; W S Dalton
Journal:  Blood       Date:  1994-05-01       Impact factor: 22.113

View more
  3 in total

1.  A novel cell-associated protection assay demonstrates the ability of certain antibiotics to protect ocular surface cell lines from subsequent clinical Staphylococcus aureus challenge.

Authors:  J B Wingard; E G Romanowski; R P Kowalski; F S Mah; Y Ling; R A Bilonick; R M Q Shanks
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

2.  Efficacy of Tulathromycin for the Treatment of Foals with Mild to Moderate Bronchopneumonia.

Authors:  D Rutenberg; M Venner; S Giguère
Journal:  J Vet Intern Med       Date:  2017-04-19       Impact factor: 3.333

3.  In vitro performances of novel co-spray-dried azithromycin/rifampicin microparticles for Rhodococcus equi disease treatment.

Authors:  Elisa Rampacci; Maria Luisa Marenzoni; Elisabetta Chiaradia; Fabrizio Passamonti; Maurizio Ricci; Marco Pepe; Mauro Coletti; Stefano Giovagnoli
Journal:  Sci Rep       Date:  2018-08-14       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.